DISCOUNT-ZERTIFIKAT - MODERNA | Market Closed - Bid/Ask 01:12:38 2024-06-12 pm EDT | After market 02:17:21 pm | |||
| 79.37 EUR | -0.79% |
|
79.54 | +0.22% |
| Current month | +1.56% | ||
| 1 month | +3.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-12 | 79.37 | -0.79% |
| 24-06-11 | 80 | +0.13% |
| 24-06-10 | 79.9 | +0.34% |
| 24-06-07 | 79.63 | +0.75% |
| 24-06-06 | 79.04 | +0.05% |
Real-time Boerse Frankfurt Warrants
Last update June 12, 2024 at 01:12 pm EDT
More quotesStatic data
| Product type | Certificati Discount |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SU6QCF |
| ISIN | DE000SU6QCF1 |
| Date issued | 2024-01-08 |
| Maturity | 2024-12-20 (191 Days) |
| Parity | 1 : 1 |
| Emission price | 68.87 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 80.25 € |
|---|---|
| Lowest since issue | 65.36 € |
| Spread | 0.03 € |
| Spread % | 0.04% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
148.4
USD
Average target price
145.2
USD
Spread / Average Target
-2.17%
- Stock Market
- Certificates
- Certificat
